Skip Navigation
ChemIDplus A TOXNET DATABASE LiteBrowseAdvanced

Substance Name: Prazosin hydrochloride [USAN:USP:JAN]
RN: 19237-84-4
UNII: X0Z7454B90
InChIKey: WFXFYZULCQKPIP-UHFFFAOYSA-N

Note

  • A selective adrenergic alpha-1 antagonist used in the treatment of heart failure, hypertension, pheochromocytoma, Raynaud's syndrome, prostatic hypertrophy, and urinary retention.

Molecular Formula

  • C19-H21-N5-O4.Cl-H

Molecular Weight

  • 419.8668
 

Classification Codes

  • Antihypertensive
  • Drug / Therapeutic Agent
  • Human Data
  • Reproductive Effect

Names and Synonyms

Name of Substance

  • Prazosin hydrochloride [USAN:USP:JAN]

Synonyms

  • 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine hydrochloride
  • 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)piperazine monohydrochloride
  • 2-(4-(2-Furoyl)piperazin-1-yl)-4-amino-6,7-dimethoxyquinazoline hydrochloride
  • CP-12,299-1
  • CP-12299-1
  • Deprazolin
  • EINECS 242-903-4
  • Furazosin hydrochloride
  • HSDB 3298
  • Hypovase
  • Hypovasole
  • Minipress
  • Minipress XL
  • NSC 292810
  • Peripress
  • Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)-, monohydrochloride
  • Pratsiol
  • Prazosin clorhidrato
  • Prazosin clorhidrato [Spanish]
  • Prazosin HCl
  • Prazosin hydrochloride
  • Sinetens
  • UNII-X0Z7454B90
  • Vasoflex

Systematic Names

  • 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)piperazine monohydrochloride
  • Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)-, monohydrochloride
  • Quinazoline, 4-amino-6,7-dimethoxy-2-(4-(2-furoyl)piperazin-1-yl)-, hydrochloride

Registry Numbers

CAS Registry Number

  • 19237-84-4

FDA UNII

  • X0Z7454B90

Other Registry Number

  • 86126-06-9

System Generated Number

  • 0019237844

Molecular Formulas

Molecular Formula

  • C19-H21-N5-O4.Cl-H

Molecular Formula Fragments

  • C19-H21-N5-O4
  • Cl-H
  • COMPONENT

Structure Descriptors

InChI

1S/C19H21N5O4.ClH/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14;/h3-4,9-11H,5-8H2,1-2H3,(H2,20,21,22);1H

InChIKey

WFXFYZULCQKPIP-UHFFFAOYSA-N

Smiles

Cl.COc1cc2nc(nc(N)c2cc1OC)N3CCN(CC3)C(=O)c4occc4

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
dog LD50 oral > 700mg/kg (700mg/kg) GASTROINTESTINAL: CHANGES IN STRUCTURE OR FUNCTION OF SALIVARY GLANDS

KIDNEY, URETER, AND BLADDER: OTHER CHANGES

GASTROINTESTINAL: NAUSEA OR VOMITING
Oyo Yakuri. Pharmacometrics. Vol. 17, Pg. 39, 1979.
human TDLo oral 285ug/kg (0.285mg/kg) VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION JAMA, Journal of the American Medical Association. Vol. 238, Pg. 157, 1977.
man TDLo oral 1714ug/kg (1.714mg/kg) BEHAVIORAL: COMA

LUNGS, THORAX, OR RESPIRATION: DYSPNEA
Human Toxicology. Vol. 4, Pg. 53, 1985.
mouse LD50 intraperitoneal 60mg/kg (60mg/kg) GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"

BEHAVIORAL: ATAXIA

BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
Oyo Yakuri. Pharmacometrics. Vol. 17, Pg. 39, 1979.
mouse LD50 intravenous 92mg/kg (92mg/kg) BEHAVIORAL: ATAXIA

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

LUNGS, THORAX, OR RESPIRATION: DYSPNEA
New Cardiovascular Drugs. Vol. 4, Pg. 1, 1986.
mouse LD50 oral 5gm/kg (5000mg/kg)   Medicamentos de Actualidad. Vol. 11, Pg. 64, 1975.
mouse LD50 subcutaneous 3100mg/kg (3100mg/kg) BEHAVIORAL: ATAXIA

LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION

BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
Oyo Yakuri. Pharmacometrics. Vol. 17, Pg. 39, 1979.
rat LD50 intraperitoneal 102mg/kg (102mg/kg) SENSE ORGANS AND SPECIAL SENSES: LACRIMATION: EYE

LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION

BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
Oyo Yakuri. Pharmacometrics. Vol. 17, Pg. 39, 1979.
rat LD50 intravenous 73mg/kg (73mg/kg) BEHAVIORAL: ATAXIA

LUNGS, THORAX, OR RESPIRATION: DYSPNEA

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD
New Cardiovascular Drugs. Vol. 4, Pg. 1, 1986.
rat LD50 oral 1950mg/kg (1950mg/kg) KIDNEY, URETER, AND BLADDER: OTHER CHANGES

GASTROINTESTINAL: NAUSEA OR VOMITING

GASTROINTESTINAL: CHANGES IN STRUCTURE OR FUNCTION OF SALIVARY GLANDS
Oyo Yakuri. Pharmacometrics. Vol. 17, Pg. 39, 1979.
rat LD50 subcutaneous 3750mg/kg (3750mg/kg) SENSE ORGANS AND SPECIAL SENSES: LACRIMATION: EYE

LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION

BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
Oyo Yakuri. Pharmacometrics. Vol. 17, Pg. 39, 1979.
women TDLo oral 10ug/kg (0.01mg/kg) SKIN AND APPENDAGES (SKIN): SWEATING: OTHER

BEHAVIORAL: COMA

VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION
Drug Intelligence and Clinical Pharmacy. Vol. 21, Pg. 723, 1987.
women TDLo oral 13mg/kg/6W-I (13mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

BRAIN AND COVERINGS: ENCEPHALITIS

BEHAVIORAL: TOXIC PSYCHOSIS
British Medical Journal. Vol. 293, Pg. 1347, 1986.